Shalini Sharp

Shalini Sharp joined Precision BioSciences’ Board of Directors in 2018. Shalini is currently the Chief Financial Officer (CFO) of Ultragenyx, a pharmaceutical company creating therapies for rare and ultra-rare diseases, and is responsible for leading their corporate finance, strategy, and information technology functions. Prior to Ultragenyx, Ms. Sharp was CFO of Agenus Inc, a publicly traded biotechnology company focused on cancer immunotherapies. Before that, she worked in corporate strategy at Elan Pharmaceuticals, in management consulting at McKinsey & Company, and in investment banking at Goldman Sachs, always in the pharmaceutical and medical device space. Ms. Sharp has over twenty years of experience in the life sciences industry and also serves as a board member at Sutro Biopharma and Array BioPharma. She holds both a BA, magna cum laude, and MBA from Harvard University.